The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1146 articles
A comprehensive guide to the National Psoriasis Foundation's findings on GLP-1 receptor agonists as adjunct therapy for psoriasis, including trial data and monitoring strategies.
The rise of GLP-1 medications is creating unexpected challenges and adaptations in the wedding dress industry, as brides experience rapid weight loss that disrupts traditional timelines and fitting processes.
Lizzo's approach to 'weight release' is more than a trend; it's a profound shift towards body autonomy, prioritizing functional health and self-defined goals over external pressures. Discover how this empowering framework can guide your own wellness journey.
Discover how serendipity and keen observation transformed drug development, leading to life-changing treatments for conditions ranging from diabetes and obesity to erectile dysfunction and wrinkles.
Two Indian firms are quietly powering the global GLP-1 weight loss boom. Learn how their manufacturing roles affect drug availability and therapy consistency.
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
New research suggests that the effectiveness of popular GLP-1 weight loss medications may significantly diminish with intermittent use. Understand the implications for your health journey.
The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
What began as a treatment for diabetes has rapidly evolved into a powerful force reshaping consumer behavior and Canada's agri-food economy. GLP-1 drugs are no longer niche medical interventions; they are becoming mainstream, driving significant changes in how Canadians eat and shop.
